COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Allopurinol in Acute Gout

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01775098
Recruitment Status : Withdrawn (because of a lack of funding)
First Posted : January 24, 2013
Last Update Posted : May 11, 2017
Information provided by (Responsible Party):
Artur de Brum-Fernandes, Université de Sherbrooke

Brief Summary:
The objectives of the present study are to determine if starting treatement of hyperuricemia with allopurinol during an acute gout crises has an impact on the duration or the severity of the crises

Condition or disease Intervention/treatment Phase
Gout Drug: allopurinol Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Allopurinol in Acute Gout The Title Will Not be Change as the Study as Been Closed.
Actual Primary Completion Date : December 2012
Actual Study Completion Date : February 2013

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Gout
MedlinePlus related topics: Gout

Arm Intervention/treatment
Experimental: Allopurinol
treatment with allopurinol
Drug: allopurinol
No arms will not be change as the study as been closed.

Placebo Comparator: placebo
placebo comparator
Drug: allopurinol
No arms will not be change as the study as been closed.

Primary Outcome Measures :
  1. Duration of the gout crises [ Time Frame: First 7 days after visit ]
    Presence of inflammatory signs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

More than 18 years old Able to sign informed consent Indication of long-term treatment with allopurinol Acute gout crisis

Exclusion Criteria:

Les than 18 years-old Unable to consent Contra-indication to allopurinol

Layout table for additonal information
Responsible Party: Artur de Brum-Fernandes, Doctor, Université de Sherbrooke Identifier: NCT01775098    
Other Study ID Numbers: Allopurinol in acute gout
First Posted: January 24, 2013    Key Record Dates
Last Update Posted: May 11, 2017
Last Verified: May 2017
Keywords provided by Artur de Brum-Fernandes, Université de Sherbrooke:
uric acid
Additional relevant MeSH terms:
Layout table for MeSH terms
Joint Diseases
Musculoskeletal Diseases
Crystal Arthropathies
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Protective Agents
Physiological Effects of Drugs